Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Reuters

03/03

Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2616340078"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616340078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616340078?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616340078","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ABOS\">Acumen Pharmaceuticals, Inc.</a> (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-03 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ABOS\">Acumen Pharmaceuticals, Inc.</a> (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL7tNLWQ:1","article_id":"2616340078","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616340078","pubTimestamp":1772542862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference               Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4539":"次新股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","EVT.AU":"EVT Ltd","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK7035":"电影和娱乐","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ABOS":"Acumen Pharmaceuticals, Inc."},"translate_title":"Acumen Pharmaceuticals将在AD/PD 2026会议上展示阿尔茨海默病治疗进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":0.9,"EVT.AU":0.9,"NDAQ":0.9},"content_text":"Acumen Pharmaceuticals to Present Alzheimer’s Treatment Advances at AD/PD 2026 Conference\n    \n\nAcumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will present one oral and two poster sessions at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Copenhagen, held in-person and online March 17-21, 2026, showcasing new data on enhanced brain delivery of sabirnetug, sabirnetug biomarker treatment responses, and new amyloid beta oligomer-targeting antibodies. Event-related materials: https://www.globenewswire.com/Tracker?data=vC5S76bf6EVdiMsTYm3IGywLE-0tGPxq2KsimNj7ovgoYx5h3S0-ZfArUXv_aerJ6pEcU_bmHh2ggdVJCkCGjg_HO-u9tDICYpRJA-yNRcM= and the July 2025 collaboration announcement link https://www.globenewswire.com/Tracker?data=SgDD5Hkz0NkBuEH5Rlps0Q3tR3OxNamB6mEBvyQqnLQAUui2ycGEJxqxTU7Ed8SrseuZSahxLt2HFZ6Ptc5hXh2HSIFjnLCYT-t8faXGEJbQYqhItA9o-jrl1Q_fe7tyLdOUAPtwt7hED1ZHFdXAuPIRfi-0mvM6HlKDE9O48vtcWJ3EFMPJZbgNkY1BvMMBBqPpG25D400S52ejfoVe0Sx45XMKo3QL2mCqOzGG5DA=.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030800PRIMZONEFULLFEED9664542) on March 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}